Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: 10q... Talked to Cliff Flowers...DB
10q
4
Apr 16, 2012 04:09PM
3
Apr 16, 2012 04:32PM
6
Apr 16, 2012 05:01PM
19
opc
Apr 16, 2012 06:13PM

What incentive is there to license? Honestly TPL makes more money racking up expenses some of which may be questionable. Don't forget that MMP revenues are also supposed to be going to Brown and Moore. Those two reasons are incentive enough (in my opinion) not to make much of an effort regarding the MMP at this point.

Regarding the controlling interest in PDS that you mentioned, Dan Leckrone and Carl Johnson are the only two members of PDS. Don't you think that Carl and Dan will continue to work out additional funding for TPL in such a way that PTSC will NEVER have controlling financial interest in PDS?

p. 8 10Q

Any additional funding provided to TPL by PDS would be in exchange for additional services and/or concessions to existing contracts. In the event that we provide funding to PDS that is not reciprocated by TPL, we may determine that we have controlling financial interest in PDS, in which case, we would be required to consolidate PDS in our consolidated financial statements.

Share
New Message
Please login to post a reply